@article {Berrodinmol.110.065193, author = {Thomas J. Berrodin and Qi Shen and Elaine M. Quinet and Matthew R. Yudt and Leonard P. Freedman and Sunil Nagpal}, title = {Identification of 5α,6α-epoxycholesterol as a Novel Modulator of LXR Activity}, elocation-id = {mol.110.065193}, year = {2010}, doi = {10.1124/mol.110.065193}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {The liver X receptors (LXRα and LXRβ) are members of the nuclear receptor superfamily that function as key transcriptional regulators of a number of biological processes including cholesterol homeostasis, lipid metabolism and keratinocyte differentiation. Natural ligands that activate LXRs include oxysterol derivatives such as 25-hydroxycholesterol, 27-hydroxycholesterol, 22(R)-hydroxycholesterol, 20(S)-hydroxychoelsterol and 24(S),25-epoxycholesterol. Related oxysterols, such as 5α,6α-epoxycholesterol (5,6-EC) are present in a number of foods and have been shown to induce atherosclerosis in animal models. Intriguingly, these oxysterols have also been detected in atherosclerotic plaques. Using a variety of biochemical and cellular assays, we demonstrate that 5,6-EC is the first dietary modulator and an endogenous LXR ligand with cell- and gene-context dependent antagonist, agonist and inverse agonist activities. In a multiplexed LXR-cofactor peptide interaction assay, 5,6-EC induced the recruitment of a number of cofactor peptides onto both LXRα and LXRβ, and showed an EC50 of approximately 2μM in peptide recruitment. Further, 5,6-EC bound to LXRα in a radiolabeled ligand displacement assay (EC50 = 76 nM), thus demonstrating it to be one of the most potent natural LXRα ligands known to date. Analysis of endogenous gene expression in various cell-based systems indicated the potential of 5,6-EC to antagonize LXR-mediated gene expression. Furthermore, it also induced the expression of some LXR-responsive genes in keratinocytes. These results clearly demonstrate that 5,6-EC is an LXR modulator that may play a role in the development of lipid disorders, such as atherosclerosis by antagonizing the agonistic action of endogenous LXR ligands.}, issn = {0026-895X}, URL = {https://molpharm.aspetjournals.org/content/early/2010/09/13/mol.110.065193}, eprint = {https://molpharm.aspetjournals.org/content/early/2010/09/13/mol.110.065193.full.pdf}, journal = {Molecular Pharmacology} }